GLP-1/GIP/Gcg

Retatrutide 20MG

Retatrutide is a next-generation triple agonist peptide simultaneously targeting GLP-1, GIP, and glucagon receptors. Phase 2 clinical data has demonstrated significant metabolic effects. This 20MG vial is intended for advanced receptor pharmacology research.

Mechanism	GLP-1 / GIP / Gcg Triple Agonist
CAS Number	2381090-08-8
Form	Lyophilized powder
Purity	≥99%
Vial	6ML sealed flip-top

Order Now View Certificate of Analysis